Navigation Links
Dendreon Announces Increased Capacity and Significant Reimbursement Decisions Supporting Broad Availability of PROVENGE
Date:6/30/2011

ancial assistance for co-pays, co-insurance, and treatment-related travel costs.

"These significant achievements support broad access to PROVENGE, the foundation of care for men with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer," said Mitchell H. Gold, M.D., president and chief executive officer of Dendreon.  "The increased capacity and positive National Coverage Decision by CMS in conjunction with the patient assistance programs will ensure patients who may benefit from treatment with PROVENGE have increased access to it."

For information about these programs, please visit www.provenge.com or call 1-877-336-3736.

PROVENGE Indication and Safety

PROVENGE was approved by the U.S. Food and Drug Administration in April 2010 as the first autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.

PROVENGE is intended solely for autologous use and is not routinely tested for transmissible infectious diseases.

The safety evaluation of PROVENGE was based on 601 prostate cancer patients in four randomized clinical trials who underwent at least one leukapheresis procedure. The most common adverse events (incidence greater than or equal to 15%) reported in patients in the PROVENGE group are chills, fatigue, fever, back pain, nausea, joint ache, and headache. Serious adverse events reported in patients in the PROVENGE group include acute infusion reactions (occurring within 1 day of infusion) and cerebrovascular events. In controlled clinical trials, severe (Grade 3) acute infusion reactions were reported in 3.5% of patients in the PROVENGE group. Reactions included chills, fever, fatigue, asthenia, dyspnea, hypoxia, bronchospasm, dizziness, headache, hypertension, muscle ache, nausea, and vomiting. No Grade 4 or 5 acute infusion react
'/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
2. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
3. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
4. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
5. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
6. Dendreon Reports Third Quarter 2008 Financial Results
7. Dendreon Announces Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
8. Dendreon Announces Webcast Presentation at Eleventh Annual BIO CEO & Investor Conference
9. Dendreon Reports Fourth Quarter and 2008 Year End Financial Results
10. Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer
11. Dendreon Announces Data Presentations and Webcast at AUA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2015)... , April 18, 2015 ... CRIS ) will be presenting data at the ... Associate of Cancer Research Annual Meeting (April 18-22 ...      (Logo: http://photos.prnewswire.com/prnh/20130418/608115 ) , ... Nicotinamide phosphoribosyltransferase (NAMPT) small molecule inhibitors program, which ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 CIO Review ... for its 20 Most Promising Pharma and Life Science ... MMIS’s MediSpend global compliance software platform for life sciences ... selected by a panel of experts and members of ... entrepreneurship. “MMIS’s MediSpend Platform has been on our radar ...
(Date:4/17/2015)... April 17, 2015  US-Australian drug discovery company, Novogen, ... of Understanding with the Feinstein Institute for Medical ... to collaborate with the objective of ... The collaboration brings together the drug discovery expertise ... of the Feinstein Institute in neurosciences and oncology. ...
(Date:4/17/2015)... Madison, WI (PRWEB) April 17, 2015 ... provide sales and marketing support for the powerful ... at the Chemical Genomics Center at the Lankenau ... LCGC’s mission is to measurably improve successful ... to HTS, by offering rare, drug-like libraries available ...
Breaking Biology Technology:Aurigene to Present its NAMPT and IRAK-4 Inhibitors Programs at AACR 2015 2MMIS Chosen by CIO Review as Top 20 Most Promising Pharma and Life Science Technology Solution Providers 2015 2Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 2Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 3Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 4Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 5Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 6BellBrook Labs and Lankenau Institute Partner to Accelerate Drug Discovery using Orthogonal Pooled Screening 2
... bulbs into power-sippers, say optics researchers at the University ... bright as a 100-watt bulb consume less electricity than ... a more pleasant light than a fluorescent bulb can., ... and micro-scale structures on the surface of a regular ...
... TorreyPines Therapeutics, Inc. (Nasdaq: TPTX ) ... after consideration of potential strategic and financing alternatives, that ... and its stockholders to liquidate the Company,s assets and ... has unanimously approved a Plan of Liquidation and Dissolution ...
... COLUMBIA, Md., May 29 Martek Biosciences Corporation (Nasdaq: ... at the 8th Annual Needham Life Sciences Conference which is ... York Palace Hotel in New York City. Peter L. ... June 11, 2009, at 2:30 p.m. Eastern Time.A live audio ...
Cached Biology Technology:Regular light bulbs made super-efficient with ultra-fast laser 2Regular light bulbs made super-efficient with ultra-fast laser 3TorreyPines Therapeutics Announces its Board of Directors' Approval of Plan of Liquidation and Dissolution 2TorreyPines Therapeutics Announces its Board of Directors' Approval of Plan of Liquidation and Dissolution 3
(Date:4/10/2015)... 10, 2015 Research and Markets ... "Security Competitive Profiles - NEC" report to ... NEC will continue to supply a range of ... with a company focus on the development of a ... Winning opportunities in the Asia-Pacific ...
(Date:4/2/2015)... In the current eight ... the strongest competitors, showing outstanding performance in recognition ... is capable of a throughput of 5.000.000 fingerprints ... be ten times faster than most competitors and ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) , ...
(Date:4/1/2015)... 1, 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces the second ... is underway to early access pre-order customers. ... at retail outlets including Walmart, Target, AT&T, Dunkin, Donuts, ... was accepted at all outlets and very easy to ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4
... Day, World Wildlife Fund and its partners in the ... to prevent the accidental maiming and killing of marine ... by fishing nets and longlines--a problem known as bycatch--while ... solutions safeguard our living oceans," said Carter Roberts, president ...
... that showcase applications ranging from early-stage disease diagnosis to ... be well represented at the 229th National Meeting of ... in San Diego. , Founded in 1876, the ACS ... largest scientific society in the world with an international ...
... researchers chiseling away at the problem of antibiotic resistance ... main cellular target in bacteria evolves to become resistant ... leading to new experimental antibiotics that are being engineered ... problem. , Led by Thomas A. Steitz, a Howard ...
Cached Biology News:Solutions that reduce death of marine life reeled in by International Smart Gear Competition 2Solutions that reduce death of marine life reeled in by International Smart Gear Competition 3Disease diagnosis, biodefense among UH chemical research projects 2Disease diagnosis, biodefense among UH chemical research projects 3Researchers make gains in understanding antibiotic resistance 2Researchers make gains in understanding antibiotic resistance 3
... a full featured, two laser, six detector analytical ... CFlow Software, and a PC for operation and ... the capabilities of the best selling flow cytometers ... Flow Cytometer System has six detectors to capture ...
Fingerprinting II Basic software is used for analyzing fingerprint sample types (electrophoretic gels, HPLC and other chromatographic patterns, spectrophotometric and densitometric curves)....
...
Fingerprinting II cluster analysis is an optional module that adds dendrogram and phylogenetic tree construction, cluster and group significance, and congruence of techniques functions to the Fingerp...
Biology Products: